Your English writing platform
Discover LudwigSuggestions(1)
Similar(60)
Among the 48 patients, no patients had acute respiratory distress syndrome, 45% were receiving catecholamines and 10% neuromuscular blockers at the time of the TTE evaluation.
Twenty-one out of 87 patients were already taking a β-blocker at the time of admission.
The positive impact of being treated with oral beta-blockers at the time of respiratory failure in ICU patients was unknown.
Most participants in the study were males, had persistent atrial fibrillation, had hypertension, and were receiving oral anticoagulants and β-blockers at the time of enrollment.
However, patients currently being treated with oral beta-blockers at the time of acute respiratory failure had consistently lower in-hospital and one-year overall mortality.
Patients taking oral β-blockers at the time of admission had lower in-hospital and 1-year mortality rates than other patients.
One patient in the RP group and eight in the SSc group were on calcium channel blockers at the time of inclusion and one of each group was on buflomedil.
Recently, Macchia et al. analyzed a database of Italian ICU patients hospitalized for sepsis and found a 28-day survival advantage in patients who were taking β-blockers at the time of admission and who subsequently developed sepsis [ 23].
Exact mechanisms of a better short term and long-term survival in patients being treated with oral beta-blockers at the time of respiratory failure remained to be explored.
Forty-nine patients (15.6%) had taken β-blockers on admission (β1 selective β-blockers: 26 patients; non-selective β-blocker: 23 patients) and 131 (42.1%, β1 selective β-blockers: 21; non-selective β-blocker: 110) had taken β-blockers at the time of discharge.
In the second situation, the patients were considered no longer exposed to TNFα blockers at the time of surgery if TNFα blockers had been withdrawn at least five half-lives before surgery (50 days for infliximab, 70 days for adalimumab, 15 days for etanercept).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com